Thursday, May 31, 2012

Novartis Drug Pasireotide LAR Shows Superior Efficacy Compared to Sandostatin LAR in Phase III Trial of Patients With Acromegaly

Results of the largest Phase III study of acromegaly patients show the novel therapy pasireotide (SOM230 structure left below) long-acting release (LAR), was significantly more effective at inducing full biochemical control compared to the current standard medical therapy, Sandostatin® LAR® (octreotide/IM injection below right structure). 

Novartis Drug Pasireotide LAR Shows Superior Efficacy Compared to Sandostatin LAR in Phase III Trial of Patients With Acromegaly:  Patients on pasireotide (SOM230) LAR were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care[1]  Acromegaly, a rare  endocrine disorder caused by excess growth hormone, can... 





Ref : http://www.novartis.com/newsroom/media-releases/en/2012/1609172.shtml

No comments: